26 September 2018 Brisbane - BGI and Maxwell Plus executed a research collaboration “A model to predict the risk of developing advanced or metastatic prostate cancer using genetic makeup and family history of cancers”. Prostate cancer is the second most common type of cancer among males in Western countries, with an estimated 165,000 new cases and 29,500 cancer deaths in 2018 alone. The objective of this prostate cancer research project is to understand the genetic makeup of prostate cancer patients and understand how significant the association is between the prevalence of prostate, breast, ovarian and colorectal cancers in the families of patients. The risk of the genetic makeup and family history will be combined into a risk model for predicting advanced or metastatic prostate cancer. All samples will be sequenced on the cutting-edge BGI genetic sequencer, MGISEQ-2000, in the BGI Australia laboratory.
“The combination of AI (artificial intelligence) and genetic sequencing data promises to be an exciting step forward in the management of prostate cancer; we are delighted to be working with the innovative and dedicated team at Maxwell Plus”, said Dr. Lynn Fink, Research Director of BGI Australia.
"We are excited at the opportunities this collaboration brings. At Maxwell Plus we know that better patient outcomes will arise through an analysis of all of a patient's data and sequencing is and will continue to be a key part of that data.", said Dr. Elliot Smith, CEO of Maxwell Plus.
Founded in 2016, Maxwell Plus is a growing Brisbane-based medical technology start-up rethinking the way disease is detected and diagnosed by combining machine learning with complex medical data the team is working to make cancer diagnosis faster, more affordable and more accurate.
BGI is the largest organization in the world in genomics research and applications. Since the BGI Australia office opened in 2016, BGI has initiated projects covering a wide range of areas via partnerships with strong local scientific research partners, such as imaging and genomics cancer, infectious disease, marine biology, and biodiversity.
+61 7 3362 0475
+61 401 861 307